Élisabeth Quoix

Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

David Planchard, Benjamin Besse, Harry J.M. Groen et al. · The Lancet Oncology · 2016 · 867 citations · Full text

Multicentre Phase 2, Medicine, Metronomic Therapy +6

Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 Patients

Thierry Le Chevalier, R. Arriagada, Élisabeth Quoix et al. · JNCI Journal of the National Cancer Institute · 1991 · 804 citations

Adaptive Radiotherapy, Surgical Oncology, First Analysis +15

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

Élisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster et al. · The Lancet · 2011 · 573 citations

Elderly Patients, Medicine, Metronomic Therapy +7

Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non–Small-Cell Lung Cancer

A Depierre, B. Milleron, Denis Moro‐Sibilot et al. · Journal of Clinical Oncology · 2002 · 569 citations

Survival of Patients With Resected N2 Non–Small-Cell Lung Cancer: Evidence for a Subclassification and Implications

Fabrice André, Dominique Grunenwald, Jean‐Pierre Pignon et al. · Journal of Clinical Oncology · 2000 · 486 citations